Repair & recovery
Pentadeca Arginate
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Also known as PDA
A BPC-related arginate analog studied as a more stable variant in tissue-repair research.
What it is
Pentadeca Arginate is a modified version of the BPC-157 sequence formulated as an arginate salt, developed with the aim of improving stability. The research base is newer and thinner than BPC-157's, and much of what is claimed about it is extrapolated rather than demonstrated.
What it's studied for
- Tissue-repair signaling by analogy to BPC-157
- Stability and handling characteristics
How it's used in practice
- Marketed as a successor to BPC-157; treat that framing with skepticism
- Any protocol discussion should acknowledge the thin evidence base
What you should know before asking about it
- Research use only; not FDA-approved
- Very limited published data, including in animals
- Newer does not mean better characterized or safer
Frequently asked questions.
- What is Pentadeca Arginate?
- Pentadeca Arginate is a modified version of the BPC-157 sequence formulated as an arginate salt, developed with the aim of improving stability. The research base is newer and thinner than BPC-157's, and much of what is claimed about it is extrapolated rather than demonstrated.
- What is Pentadeca Arginate studied for?
- Published and ongoing research looks at tissue-repair signaling by analogy to BPC-157; stability and handling characteristics. These are areas of study, not promised outcomes.
- Is Pentadeca Arginate FDA-approved?
- Pentadeca Arginate has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
- How is Pentadeca Arginate typically used?
- Marketed as a successor to BPC-157; treat that framing with skepticism Any protocol discussion should acknowledge the thin evidence base Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Pentadeca Arginate?
- Research use only; not FDA-approved Very limited published data, including in animals Newer does not mean better characterized or safer
Sources
- 1.Published literature on Pentadeca Arginate PDA— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Repair & recovery
BPC-157
A synthetic pentadecapeptide sequence studied in preclinical models of tendon, ligament, muscle and gut-lining repair.
TB-500
A fragment of thymosin beta-4 studied for cell migration, flexibility and scar remodeling in preclinical injury models.
GHK-Cu
A naturally occurring copper-binding tripeptide studied for collagen synthesis, skin quality and gene-expression effects.